CoChat

Bevacizumab-Induced Normalization of Blood Vessels in Tumors Hampers Antibody Uptake

Open access
Arjaans, Marlous, Oude Munnink, Thijs H., Oosting, Sjoukje F., Terwisscha van Scheltinga, Anton G.T., Gietema, Jourik A., Garbacik, Erik T., Timmer-Bosscha, Hetty, Lub-de Hooge, Marjolijn N., Schröder, Carolina P., de Vries, Elisabeth G.E. · 2013 · Cancer Research
Cited by 121

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

In solid tumors, angiogenesis occurs in the setting of a defective vasculature and impaired lymphatic drainage that is associated with increased vascular permeability and enhanced tumor permeability. These universal aspects of the tumor microenvironment can have a marked influence on intratumoral drug delivery that may often be underappreciated. In this study, we investigated the effect of blood vessel normalization in tumors by the antiangiogenic drug bevacizumab on antibody uptake by tumors. In mouse xenograft models of human ovarian and esophageal cancer (SKOV-3 and OE19), we evaluated antibody uptake in tumors by positron emission tomographic imaging 24 and 144 hours after injection of 89Zr-trastuzumab (SKOV-3 and OE19), 89Zr-bevacizumab (SKOV-3), or 89Zr-IgG (SKOV-3) before or after treatment with bevacizumab. Intratumor distribution was assessed by fluorescence microscopy along with mean vessel density (MVD) and vessel normalization. Notably, bevacizumab treatment decreased tumor uptake and intratumoral accumulation compared with baseline in the tumor models relative to controls. Bevacizumab treatment also reduced MVD in tumors and increased vessel pericyte coverage. These findings are clinically important, suggesting caution in designing combinatorial trials with therapeutic antibodies due to a possible reduction in tumoral accumulation that may be caused by bevacizumab cotreatment. Cancer Res; 73(11); 3347–55. ©2013 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-12-3518

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 121

Metadata

Authors
Arjaans, M., Oude Munnink, T. H., Oosting, S. F., Terwisscha van Scheltinga, A. G. T., Gietema, J. A., Garbacik, E. T., Timmer-Bosscha, H., Lub-de Hooge, M. N., Schröder, C. P., & de Vries, E. G. E.
Venue
Cancer Research
Published
2013-05-30
Volume
73
Issue
11
Pages
3347-3355
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2161962458
Cited by
121
References
13
FWCI
6.59
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bevacizumab-Induced Normalization of Blood Vessels in Tumors Hampers Antibody Uptake. https://app.cochat.ai/papers/10.1158/0008-5472.can-12-3518
The paper
Arjaans, M., Oude Munnink, T. H., Oosting, S. F., Terwisscha van Scheltinga, A. G. T., Gietema, J. A., Garbacik, E. T., Timmer-Bosscha, H., Lub-de Hooge, M. N., Schröder, C. P., & de Vries, E. G. E. (2013). Bevacizumab-Induced Normalization of Blood Vessels in Tumors Hampers Antibody Uptake. Cancer Research. https://doi.org/10.1158/0008-5472.can-12-3518

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.